MapleStory Expands Game Universe in Neo Part One Update With New Archer Class, Kain
MapleStory, the iconic free-to-play global MMORPG from Nexon, has today launched Neo: Darkness Ascending, Part One of its summer update, the largest content update to the game in 2021. Neo Part One adds an all new area, Cernium, increases the max level to 300, and offers special limited-time events today, in addition to adding a new Nova Archer job, Kain, on June 23.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005162/en/
MAPLESTORY EXPANDS GAME UNIVERSE IN NEO PART ONE UPDATE WITH NEW ARCHER CLASS, KAIN (Graphic: Business Wire)
First, a new Nova Archer job – the Darkness Chaser, Kain – joins the game on June 23. Kain is a powerful archer, fighting to recover his lost past after discovering that his organization had deceived him. Using the Whispershot, a one-handed weapon, alongside melee weapons from his Weapon Belt, Kain commands an effective and versatile weapons mastery to inflict critical hits on his enemies.
The border between two worlds has disappeared and Cernium, City of the Gods, has reappeared. New area Cernium is now available in-game and brings new challenges and quests to all players. For an added boost, a special power called Sacred Power is now available to aid in the battle against monsters inhabiting the Grandis Continent. Sacred Power is acquired by equipping Sacred Symbols, which can be enhanced to increase Sacred Power as well as main stats.
Starting today, the maximum character level is increased from 275 to 300 and the amount of EXP required to level up between levels 210-250 has been reduced. The update also includes increased EXP rewards for Arcane River quests, and modifies the character death penalty to a decreased drop rate percentage instead of overall experience lost.
Part One of the Neo Update also brings the new Neo Castle event to MapleStory. Neo Castle, an area shrouded in mystery, was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events with the following features and shops available now:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of improvements that can be used to enhance items and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by battling bosses and can be used to purchase a variety of rare items
- Neo Meso Shop: The Meso shop is stocked full of powerful items that can be purchased using Mesos
The Neo Update also includes the following updates and features:
Burning World and Tera Burning
Burning World and Tera Burning events return to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon.
The Better Maple Project brings a host of new improvements for overall improved gameplay including:
- The V Matrix has been improved for easier use
- Boss Battles have been improved and a new boss entry system has been added, allowing players to move to the waiting area immediately from the current channel simply by selecting the boss, difficulty and pressing “GO”
- Skill Tooltips have been widened for better legibility and understanding of skill descriptions
- Equipped item functionality has been improved, allowing players the ability to compare equipped items with other items linked in chat
- The Clean Slate Scroll has been updated, and while in possession, is changed to a Pure Clean Slate Scroll to protect the item from being destroyed when it fails
- A Notification has been added to alert players when Safeguard is automatically disabled during Star Force enhancement
- Meso Market trades that are in progress for other characters in the same world have been updated and can be viewed in addition to canceling or receiving trades
- The Meso Market’s daily listing limit has been increased to 20
- Maplers can now purchase Mu Gong's Soul Shard from the Mu Lung Dojo Point Shop
To learn more about MapleStory, please visit http://maplestory.nexon.net
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc.https://www.nexon.com/
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release
Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an
Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release
The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,
Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release
Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom